Jiangsu Hengrui Pharmaceuticals at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Jiangsu Hengrui Pharmaceuticals brings 2 presentations to ObesityWeek 2026 in National Harbor. Its posters report phase 3 HARBOR-1 results for HRS-7535 in weight management among Chinese adults with overweight or obesity, plus a subgroup analysis of the drug's effect on glycemic status in prediabetes.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Jiangsu Hengrui Pharmaceuticals Lianyungang, China | |
Pharmaceutical company whose obesity pipeline includes HRS-7535, an oral GLP-1 receptor agonist in phase 3. | Poster Sun Nov 15 2:30pm–3:30pm HRS-7535 for Weight Management in Chinese Adults with Overweight or Obesity: Phase 3 HARBOR-1 Study Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm HRS-7535 Effect on Glycaemic Status in Prediabetes: HARBOR-1 Subgroup Analysis Interventional and clinical studiesObesity pharmacotherapy and drug development |
Find decision makers at Jiangsu Hengrui Pharmaceuticals
Tell us what you sell and we’ll find the people at Jiangsu Hengrui Pharmaceuticals most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction